Compare ServiceNow Inc (NOW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ServiceNow Inc vs TG Therapeutics Inc — how do they compare? ServiceNow Inc trades at $124.57 (market cap $131.86B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: ServiceNow Inc is far larger — about 17.3× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals.
| NOW | TGTX | |
|---|---|---|
Market Cap | $131.86B | $7.64B |
Sector | Technology | Health |
52-Week High | $192.23 | $59.06 |
52-Week Low | $83.00 | $26.94 |
Enterprise Value | $135.65B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $127.44, up 2.05% today, with a bullish technical outlook supported by moving averages but overbought RSI signals. Revenue grew to $13.28B in 2025, with a net income margin of 11.34%, though high P/E of 79.71 indicates premium valuation. Recent news highlights AI-driven growth opportunities, including partnerships and conference presentations in June 2026.
The stock offers growth potential from AI adoption and strong cash flows, but faces risks from elevated valuations and competitive pressures. Analyst consensus is strongly bullish with an average price target of $138.26, though investors should monitor earnings consistency and macroeconomic headwinds.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
